Roche Invests in Blueprint Medicines to Develop Lung-Cancer Drug
14 Luglio 2020 - 8:08AM
Dow Jones News
By Jessica Sier
Roche Holding AG said Tuesday that it will invest and codevelop
a lung-cancer drug with U.S. company Blueprint Medicines Corp.
The two companies will develop pralsetinib, a therapy for people
with RET-altered nonsmall cell lung cancer, various types of
thyroid cancer and other solid tumours.
The Swiss drug company said it will pay $675 million in cash
upfront, as well as a $100 million equity investment in Blueprint
Medicines.
The U.S.-based drug company is eligible to receive up to $927
million in potential milestones, plus royalties on net product
sales outside the U.S.
Roche said the agreement gives it exclusive rights for global
co-development and commercialization outside the U.S. and excluding
Greater China.
Write to Jessica Sier at jessica.sier@wsj.com
(END) Dow Jones Newswires
July 14, 2020 01:53 ET (05:53 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Blueprint Medicines (NASDAQ:BPMC)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Blueprint Medicines (NASDAQ:BPMC)
Storico
Da Lug 2023 a Lug 2024
